FOREWORD

The Standard Treatment Guidelines (STG) and the National Essential Medicine List for Tanzania (NEMLIT) was first published in 1991. The fourth edition includes new sections on symptoms and syndrome. The STGs have been updated and are consistent with current national guidelines for diagnosis and management of common diseases. The guidelines also reflect changes in the management of various diseases including asthma and hypertension following recommendations from WHO and experts from international medical associations and agencies. There have been improvements in the format of treatment regimens, showing more clearly the classification of medicines by level of health care within the treatment guidelines, and not just in the NEMLIT.

The STG and NEMLIT aims at providing health practitioners with standardized guidance in making decisions about appropriate health care for specific conditions found in Tanzania. By using STGs, prescribing practices can be rationalized and patient outcomes can be improved while making optimum use of the limited resources for medicines. The NEMLIT attached to the STG retains its purpose of identifying medicines that are considered essential for the treatment of common disease conditions in Tanzania. The medicine list is in line with the World Health Organization (WHO) recommendations under Tanzania conditions. It follows the principles and concepts of essential medicines so as to simplify the management of medicines supply and support a streamlined logistics system.

This set of tools is meant to be a guide for quick reference and its recommendations are valid for most presentations of the conditions covered. Nevertheless, clinical judgment and experience will always prevail for adjustment of treatment in individual cases when necessary.

This new edition of STGs provides Medicines and Therapeutics Committees (MTCs) at our health institutions an opportunity to strengthen their role in improving therapeutics and management of medicines in practice. MTCs are requested to promote the concepts of evidence based selection of medicines and cost-effective treatment protocols and facilitate STGs to be applied in their specific practice settings, translating and incorporating into local guidelines, formularies and in-service training programmes.

The Ministry’s policy is that all public and private health workers in Tanzania will promote and adhere to these Standard Treatment Guidelines, and that prescribing, purchasing, labeling and dispensing of medicines should be by generic names as much as possible, and consistent with the level classification in the STGs and NEMLIT.

It is my hope that all health workers in Tanzania will find this document a useful tool in management of patients’ illnesses.

Hon. Dr. Hussein Mwinyi (MP)
MINISTER FOR HEALTH AND SOCIAL WELFARE
ACKNOWLEDGEMENTS

The Ministry of Health and Social Welfare greatly appreciates the support of the Health Sector Program Support IV in the course of development of the Standard Treatment Guidelines and Essential Medicines List. The Ministry expresses much gratitude to the World Health Organization (WHO) for providing the technical support in reviewing these guidelines and the Danish Internation Developments Agency (DANIDA) for the financial support. It is anticipated that, the guidelines will be useful as tools for health professionals.

The Ministry wishes to acknowledge the following members of the National Medicines and Therapeutic Committee (NMTC) for their valuable inputs, guidance and approval of the document:

Dr. Donan W. Mmbando  Chief Medical Officer and Chairperson of the NMTC
Mr. Henry Irunde  Chief Pharmacist and Secretary of NMTC
Dr. Margaret E. Mhando  Director, Curative Services – MoHSW
Dr. Mohammed A. Mohammed  Director, Health Quality Assurance – MoHSW
Dr. John Rwegasha  Consultant Physician (Gastroenterologist) – MNH
Dr. Daudi Mavura  Consultant, Dermatologist - KCMC
Dr. Robert Mvungi  Consultant Cardiologist – MNH
Mr. Emmanuel Yohana  Clinical Pharmacist, Mirembe Psychatric Hospital
Mr. George Mlavwasi  Head, Pharmacy Department – MNH
Dr. Baraka Nzobo  Dental officer, Morogoro Regional Hospital
Dr. Charles Massambu  Assistant Director, Diagnostics – MoHSW
Dr. Doroth Kijugu  Regional Medical Officer – Singida
Dr. Rodrick Kisenge  Consultant Paediatrician – MUHAS
Mr. Hiiti Sillo  Director General, TFDA
Mr. Heri Mchunga  Director Logistics- MSD
Prof. Mary Jande  Pharmacologist - BUHAS

The preparation of the guidelines has been made possible by the contribution of a review group composed of multi-sectoral and interdisciplinary experts. The Ministry acknowledges all those who were involved in the development of the document and appreciates a sincere contribution of:

Mr. Hanif Nazerali  Adviser Pharmaceuticals – MoHSW
Dr. Linda Ezekiel  Consultant, Renal Unit – MNH
Ms. Siana Mapunjo  Principal Pharmacist - MoHSW
Winna Shango  Principal Pharmacist  MoHSW
Ms. Anita Masenge  Senior Pharmacist - MoHSW
Dr. Y.M Kapona  Consultant Obstetric/Gynecologist- MNH
Dr. James Rwehabura  Consultant Haematologist – MNH
Dr. Edna Majaliwa  Consultant Paediatrician – MNH
Dr. Dominista Kombe  Medical Oncologist – ORCI
Dr. H.K Shaban  Consultant Neurosurgeon – MOI
Ms. Eva Muro  Clinical Pharmacist – KCMC
Dr. Sara Urassa  Physician – KCMC
Dr. Gileard Masenga  Obstetric/Gynecologist – KCMC
Dr. Joyce Mugasa  Psychiatrist – MNH
Dr. Kitange Jamhuri  Physician – Temeke Municipal Hospital
Dr. Henri Swai  ENT Surgeon
Dr. Judith Mwende  Paediatric Ophthalmology – MNH
Dr. Sira Owibingire  Dental Surgeon – MNH
Dr. Sabas Kimboka  Nutritionist – TFNC
Dr. Neema Rajabu  Physician – Mwananyamala Municipal Hospital
Dr. Innocent Mwombeki  Medical Officer, Mirembe Hospital
Mr. Kitundu W.Y.S  Principal Pharmacist – MoHSW
Dr. Bernedetha R. Shillio  Paediatric and Community Ophthalmologist – MoHSW
Dr. Anath Rwebembera  Paediatrician – NACP
Dr. Allan Tarimo  Medical Doctor- NTLP
Dr. Marero M.W  Medical Doctor – NMCP
Ms. Albina Kirango  Pharmacist- ORCI
Ms. Rachel Kaposwe  Principal Nursing Officer RCH program
Dr. Mcharo Cuthbert  Orthopaedics – MOI
Dr. Eppaphroditus Msambili  Clinical Officer – Bahi District Council
Dr. Mashafi JM  Consultant Obstetric/ Gynecologist - AGOTA

REGINA L. KIKULI
ACTING - PERMANENT SECRETARY
HOW TO USE THE DOCUMENT

The guideline covers chapters of common diseases in Tanzania. Most chapters start with a title, a brief description of the topic, common clinical signs and symptoms of each disease, the diagnosis and differentials, investigations, treatments and supportive care. The document comprises the national Essential Medicines List (NEMLIT) which will be used in the public health facilities. The medicines will be used to treat the majority of public health problems and they should be available to health facilities at all time. The guideline also makes provision for referral of patients to higher health facilities.

The indices for all medicines used are found at the back of the guide book, together with the information on how to report the adverse drug reactions. All health care workers are encouraged to report suspected adverse drugs reactions (ADR) when the reaction is potentially serious or clinically significant. The guideline also, makes provision for referral of patients to higher health facilities see the referral form. The last pages of the guideline contain annexes, references as well as the Essential Medicines List.

It is important to remember that the recommended treatments provided in this document are evidence, clinically approved and are in consistent with the already existing WHO guidelines. Comments that aim to improve these treatment guidelines will be appreciated all the time and the form for that purpose is appended.
# TABLE OF CONTENTS

FOREWORD ................................................................................................................. i

ACKNOWLEDGMENT ..................................................................................................... ii

TABLE OF CONTENTS .................................................................................................. iv

ABBREVIATIONS AND SYMBOLS................................................................................. xiv

## CHAPTER ONE

SYNDROMIC APPROACH .............................................................................................. 1

1.0 PAIN ..................................................................................................................... 1

2.0 HEADACHE ............................................................................................................ 3

3.0 FEVER ................................................................................................................... 7

4.0 COUGH ................................................................................................................. 8

5.0 CONVULSION ....................................................................................................... 8

6.0 SHOCK ................................................................................................................. 10

7.0 DEHYDRATION ................................................................................................... 12

8.0 HYPOGLYCEMIA ............................................................................................... 14

## CHAPTER TWO

ORAL AND DENTAL CONDITION ............................................................................ 17

1.0 PERIODONTAL CONDITIONS ............................................................................... 17

2.0 DENTAL CARIES ............................................................................................... 19

3.0 ODONTOGENIC AND NON-ODONTOGENIC OROFACIAL INFECTIONS .......... 21

4.0 FUNGAL INFECTIONS ......................................................................................... 27

5.0 VIRAL INFECTIONS ........................................................................................... 28

6.0 APHTHOUS ULCERATION ................................................................................. 29

7.0 POST EXTRACTION BLEEDING ......................................................................... 30
8.0 TOOTH SENSITIVITIES .........................................................................................31
9.0 TOOTH ERUPTION, SHEDDING AND EDENTULOUSNESS.................................31
10.0 MALOCCLUSIONS .............................................................................................32
11.0 TRAUMATIC DENTAL INJURIES ......................................................................33
12.0 TUMOURS AND TUMOUR-LIKE CONDITIONS OF ORAL CAVITY AND FACIAL REGION ........................................................................................................ 34

CHAPTER THREE .....................................................................................................36
GASTRO INTESTINAL DISEASE CONDITION ............................................................36
1. 0 INFECTIONS OF GASTROINTESTINAL TRACT ...................................................36
2. 0 DISORDERS OF GASTROINTESTINAL TRACT ...................................................50
3. 0 DISORDERS OF THE LIVER AND BILLIARY TRACT ..........................................65

CHAPTER FOUR .....................................................................................................36
RESPIRATORY DISEASE CONDITIONS ......................................................................71
1. 0 ACUTE RESPIRATORY INFECTIONS (ARI) .........................................................71
2. 0 BRONCHOSPASM ...............................................................................................74
3. 0 BRONCHITIS .....................................................................................................78
4. 0 CHRONIC OBSTRUCTIVE PULMONARY DISEASE ..........................................79
5. 0 OTHER RESPIRATORY INFECTIONS ..................................................................81

CHAPTER FIVE .......................................................................................................85
OBSTETRICAL/GYNAECOLOGICAL DISEASE CONDITIONS & CONTRACEPTION .85
1. 0 INFECTION OF THE GENITAL-URINARY TACT ..................................................85
2. 0 ABORTION .........................................................................................................86
3. 0 PREMATURE RAPTURE OF MEMBRANE ............................................................87
4. 0 PROPHYLAXIS FOR CAESARIAN SECTION ......................................................88
5. 0 NAUSEA AND VOMITING IN PREGNANCY .......................................................88
6. 0 ANAEMIA DURING PREGNANCY ...................................................................89
7.0 HYPERTENSION IN PREGNANCY .................................................................90
8.0 DIABETES IN PREGNANCY ......................................................................93
9.0 HEART BURN IN PREGNANCY .............................................................93
10.0 RESPIRATORY DISTRESS SYNDROME ..................................................94
11.0 STIMULATION OF LABOUR AND MYOMETRIAL RELAXATION ..........94
12.0 TERMINATION OF PREGNANCY .........................................................96
13.0 PREGNANCY AND LACTATION .........................................................96
14.0 PELVIC INFLAMMATORY DISEASES .................................................96
15.0 HORMONAL CONTRACEPTION .........................................................97
16.0 ANTEPARTUM HAEMORRHAGE (APH) ...............................................99
17.0 DYSMENORRHOEA ...............................................................................101

CHAPTER SIX .........................................................................................102
CARDIOVASCULAR DISEASE CONDITIONS ...........................................104
1.0 INFECTIVE ENDOCARDITIS ...............................................................104
2.0 RHEUMATIC FEVER ..........................................................................107
3.0 VALVULAR HEART DISEASE AND CONGENITAL STRUCTURAL HEART DISEASE...........109
4.0 HYPERTENSION ...............................................................................110
5.0 HEART FAILURE ...............................................................................116
6.0 PULMONARY OEDEMA ......................................................................122
7.0 ACUTE CORONARY SYNDROMES ....................................................125
8.0 CHRONIC STABLE ANGINA PECTORIS ..........................................128
9.0 ATHEROSCLEROTIC PERIPHERAL DISEASE ....................................129
10.0 ACUTE PULMONARY EMBOLISM ..................................................130
11.0 CARDIAC ARRHYTHMIAS/ DYSRHYTHMIAS ..................................131
12.0 HEART BLOCK (SECOND OR THIRD DEGREE) ..............................136
13.0 SINUS BRADYCARDIA & SINUS ARREST ........................................137
Figure 1: Hypertension Management flow diagram

STRATIFY ACCORDING TO ADDED RISK (as in risk chart below)

LOW ADDED RISK

Monitor BP & Other risk factor for 6-12months

SBP ≥ 140 or DBP ≥ 90

SBP ≤ 140 or DBP ≤ 90

Continue to Monitor

MODERATE ADDED RISK

Monitor BP & Other risk factor for 3-6months

SBP ≤ 140 or DBP ≤ 90

HIGH ADDED RISK

SBP ≥ 140 or DBP ≥ 90

BEGIN DRUG TREATMENT

LIFE STYLE MODIFICATION AS APPROPRIATE
Table 7: Major Risk factors, Target Organ Damage and Associated Clinical Condition

<table>
<thead>
<tr>
<th>Major Risk factors</th>
<th>Target organ damage</th>
<th>Associated Clinical condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of SBP &amp; DBP</td>
<td>Left Ventricular Hypertrophy based on the ECG</td>
<td>Coronary Artery Disease</td>
</tr>
<tr>
<td>Smoking</td>
<td>Micro-Albuminuria: Albumin/Creatinine ratio 3 - 30mg/mmol</td>
<td>Heart Failure</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>Slightly elevated Creatinine</td>
<td>Chronic Kidney Disease</td>
</tr>
<tr>
<td>• Total Cholesterol &lt; 5mmol/l or</td>
<td>Men 115 - 133μmol/l Women 107 – 124μmol/l</td>
<td>Albumin Creatinine ratio &gt;30mg/mmol</td>
</tr>
<tr>
<td>• LDL &gt;3.0mmol/l or</td>
<td></td>
<td>Stroke or Transient Ischaemic Attack</td>
</tr>
<tr>
<td>• HDL &lt; 1mmol/l men, &lt;1.2mmol/l women</td>
<td></td>
<td>Peripheral Vascular Disease</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td></td>
<td>Advanced retinopathy</td>
</tr>
<tr>
<td>Family history of premature Ischaemic Heart Ord coronary artery disease Men &lt;55 years, Women &lt;60 years</td>
<td></td>
<td>Haemorrhage, or Exudates Papilloedema</td>
</tr>
<tr>
<td>Waist Circumference – Abdominal Obesity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men ≥ 102cm Women ≥ 88cm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Treatment Objective:**

**Achieve and maintain the target BP:** In most cases the target BP should be: systolic below 140 mmHg and diastolic below 90 mmHg. **Achieve target BP** in special cases as: In diabetic patients and patients with cardiac or renal impairment, target BP should be below 130/80 mmHg; Prevent and treat associated cardiovascular risks such as dyslipidemia and lifestyle modification.

**Non – pharmacological therapy**

Lifestyle modification:

- Weight Reduction; Maintain ideal body weight BMI 18.5 – 24.9kg/m²
- Adopt DASH* eating plan; Consume a diet rich in fibre - fruits, vegetable, unrefined carbohydrate and low fat dairy products with reduced content of saturated and total fat
- Dietary Sodium; Reduce dietary sodium intake no more than 1000mmol/l (2.4gm sodium or 6gm sodium chloride
- Physical Activity; Engage in regular activity such as a brisk walking at least 30min/day most days a week
- Stop using all tobacco products
- Moderation of alcohol consumption; Limit consumption to no more than 2 drinks per day in men and no more than one drink per day in Women and light person

*DASH – Dietary Appropriate to Stop Hypertension
Pharmacological therapy

First line treatment without compelling indications:
Low Dose Thiazide diuretics + Potassium sparing e.g. Bendroflumethiazide 2.5 -5mg/d, Hydrochlothiazide 12.5 -25mg/d + Spironolactone 25mg daily.

Second line treatment with compelling indications:

<table>
<thead>
<tr>
<th>Compelling indications</th>
<th>Drug class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angina</td>
<td>• β-blocker or Long acting calcium channel blocker</td>
</tr>
<tr>
<td>Prior or Post-myocardial infarct</td>
<td>• β-blocker and ACE inhibitor</td>
</tr>
<tr>
<td></td>
<td>• If s-blocker contraindicated: Long acting calcium channel blocker eg verapamil</td>
</tr>
<tr>
<td>Heart failure</td>
<td>• ACE inhibitor and Carvedilol</td>
</tr>
<tr>
<td>For volume overload:</td>
<td>• Diuretics – Spironolactone Furosemide</td>
</tr>
<tr>
<td>Left ventricular hypertrophy (confirmed by ECG)</td>
<td>ACE inhibitor or ARB</td>
</tr>
<tr>
<td>Stroke: secondary prevention</td>
<td>Hydrochlorothiazide or Indapimide and ACE inhibitor</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>ACE inhibitor or ARB, usually in combination with diuretic</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>ACE inhibitor, usually in combination with diuretic</td>
</tr>
<tr>
<td>Isolated systolic hypertension</td>
<td>Hydrochlorothiazide or Long acting calcium channel blocker</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Methylodopa or Hydralazine (Avoid ACEI/ARB tetratogenic)</td>
</tr>
<tr>
<td>Prostatism</td>
<td>alpha-blocker</td>
</tr>
<tr>
<td>Elderly</td>
<td>CCB</td>
</tr>
</tbody>
</table>

Recommended Medicines for Treatment of Hypertension

<table>
<thead>
<tr>
<th>S/N</th>
<th>CLASS</th>
<th>DRUG</th>
<th>DOSAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>01.</td>
<td>Thiazide Diuretics</td>
<td>Bendroflumethiazide</td>
<td>5mg once daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hydrochlothiazide</td>
<td>12.5mg daily</td>
</tr>
<tr>
<td>02.</td>
<td>Loop Diuretics</td>
<td>Furosemide</td>
<td>40mg- 80mg daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Torasemide</td>
<td>2.5mg – 5mg daily</td>
</tr>
<tr>
<td>03.</td>
<td>Potassium Sparing Diuretics</td>
<td>Spirinolactone</td>
<td>25mg once daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eplerenone</td>
<td>25mg once daily</td>
</tr>
<tr>
<td>04.</td>
<td>Central Adrenergic Inhibitor</td>
<td>Methylodopa</td>
<td>250mg 12hrly</td>
</tr>
<tr>
<td></td>
<td>Clonidine</td>
<td>50µg 8hrly</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>-----------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>05. Beta Blockers</td>
<td>Propranolol</td>
<td>80mg 12 hrly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atenolol</td>
<td>50 – 100mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metoprolol</td>
<td>100mg 12hrly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carvedilol</td>
<td>12.5 -25mg daily</td>
<td></td>
</tr>
<tr>
<td>06. ACE Inhibitors</td>
<td>Captopril</td>
<td>12.5mg- 25mg 12hrly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enalapril</td>
<td>5- 20mg daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Losartan</td>
<td>50 -100mg daily</td>
<td></td>
</tr>
<tr>
<td>07. Calcium channel blockers – CCB</td>
<td>Nifedipine SR</td>
<td>10- 20mg 12hrly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amlodipine</td>
<td>5 – 10mg once daily</td>
<td></td>
</tr>
<tr>
<td>08. Direct Vasodilators</td>
<td>Hydralazine</td>
<td>25mg twice daily</td>
<td></td>
</tr>
</tbody>
</table>

**Referral**
Referral is dynamic and patients can be referred up to a specialist or down to PHC when controlled. Consultation without referral may be all that is necessary.
Referrals are indicated when:
- Resistant (Refractory) Hypertension
- All cases where secondary hypertension is suspected
- Complicated hypertensive urgency/emergencies
- Hypertension with Heart Failure
- When patients are young (<30 years) or blood pressure is severe or refractory to treatment.

**Resistant (Refractory) Hypertension**
Hypertension that remain >140/90mmHg despite the use of 3 antihypertensive drugs in a rational combination at full doses and including a diuretic. Consider all correctable causes of refractory hypertension, before you refer.

**Hypertensive urgency**
Symptomatic severe hypertension BP DBP >110 mmHg and/or 180mmmmHg with evidence of Target Organ Damage or grade III/IV Retinopathy with no immediate life-threatening neurological or cardiac complication such seen in emergencies

**Note:** All patient hypertensive urgency should be treated in hospital

**Treatment goal** to lower DBP to 100mmg slowly over 48 -72 hour this can be achieved with two oral agents preferably
- Long acting Calcium Channel Blocker
- ACE Inhibitor use in low dosage initially
- Beta Blocker
- Diuretic – Thiazide or Loop diuretics Furosemide beneficial in renal insufficiency & pulmonary oedema and potentiate above other classes

**Hypertensive Emergency**
A marked elevated blood pressure systolic BP ≥ 180mmHg and/or a diastolic BP ≥130mmHg associated with life threatening situations one or more of the following:
- Unstable angina/Myocardial Infarction
- Hypertensive Encephalopathy e.g. severe headache, visual disturbances, confusion, coma or seizures which may result in cerebral haemorrhage
- Acute left ventricular failure with severe pulmonary oedema (extreme breathlessness at rest)
- Excessive circulating catecholamines: e.g. phaeochromocytoma – rare cause of emergency; food or drug interaction with monoamine oxidase inhibitors
- Rapidly progressive renal failure
- Acute aortic dissection
- Eclampsia and severe pre-eclampsia

**Treatment goal** require immediate lowering of BP usually with parental therapy preferably
Intravenous agents as infusion with strictly monitoring of haemodynamics in high care depended unit or intensive care unit in the hospital
Preferable intravenous drugs are
- Nitroglycerin (glyceryl trinitrate)
- Hydralazine or Dihydralazine

### 5.0 HEART FAILURE

#### 5.1 Acute Heart Failure (AHF) or Decompensated Acute Heart Failure (DAHF)

AHF defined as rapid or gradual onset of signs & symptoms of heart failure that result on urgent unplanned hospitalization or Emergency Medicine Department visits. The Clinical Signs & symptoms are significantly life threatening.

If the above features occurs in patient diagnosed with structurally heart disease categarize as **Decompansated Acute Heart Failure (DAHF)**.

The cause and immediate precipitating factor(s) of the AHF must be identified and treated to prevent further damage to the heart.

**Causes**
- Decompensation of pre-existing chronic Heart Failure eg Cardiomyopathy, Peripartum Cardiomyopathy
- Acute Valvular Regurgitation – AR, MR 2° endocarditis, rupture of chordae tendinae
- Worsening pre-existing Valvular Disease – MS MR AR AS
- Severe Aortic Stenosis
- Hypertensive crisis
- Acute Coronary Syndrome - NSTEMI/STEMI, RV infarction, Mechanical complication of ACS
- Acute arrhythmias – VT /VF AF/flutter or other SVTs
- Acute Severe Myocarditis
- Aortic Dissection - Acute/chronic
- Pericardial Effusion with Cardiac tamponade